ArticleAlimentary pharmacology & therapeutics2023
Effects of social determinants of health on mortality and incident liver-related events and cardiovascular disease in steatotic liver disease.
Article in Alimentary pharmacology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Joint effects of social determinants of health on NAFLD mortality: the mediating role of phenotypic age acceleration.GeroScience · 2026Article
- Socioeconomic Factors and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Characterizing Social Determinants of Health in Patients With Type 2 Diabetes and Liver Disease: Cross-Sectional Survey Study.JMIR formative research · 2026Article
- The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.Nature reviews. Cardiology · 2026Review
- Social determinants disadvantage score and liver health in the All of Us Research Program.European journal of epidemiology · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Adverse Social Factors: An Analysis UsingGastro hep advances · 2026Article
- Neighborhood Social Cohesion Associated With Chronic Liver Disease Prevalence and All-Cause Mortality.Gastro hep advances · 2026Article
- The association between neighborhood context, allostatic load, and metabolic dysfunction-associated steatosis liver disease in Mexican-origin farmworkers along the Southern Arizona US/Mexico border.SSM - population health · 2025Article
- Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Cross-sectional Study in Asymptomatic Individuals in Greater Vancouver.Journal of clinical and translational hepatology · 2025Article
- Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Journal of translational medicine · 2025Article
- Feasible and acceptable social drivers of health screening among patients with chronic liver disease.Hepatology communications · 2025Article
- Social determinants of health (SDOH) associated with the risk of all-cause mortality and life expectancy in US adults with cardiovascular-kidney-metabolic syndrome: a NHANES 2001-2018 cohort study.BMC cardiovascular disorders · 2025Article
- Physical activity, diet, and social determinants of health associate with health related quality of life and fibrosis in MASLD.Scientific reports · 2025Article
- Outcomes in Acute Decompensated Congestive Heart Failure Admissions with Chronic Liver Disease: A Nationwide Analysis Using the National Inpatient Sample.Medical sciences (Basel, Switzerland) · 2025Article
- Envisioning how to advance the MASH field.Nature reviews. Gastroenterology & hepatology · 2024Review
- Food inequity and insecurity and MASLD: burden, challenges, and interventions.Nature reviews. Gastroenterology & hepatology · 2024Review
- Population screening for cirrhosis.Hepatology communications · 2024Review
- Screening for social determinants of health among populations at risk for MASLD: a scoping review.Frontiers in public health · 2024Article
- Editorial: Social determinants of health in steatotic liver disease-Generating community-level data to maximise community impact.Alimentary pharmacology & therapeutics · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSocial determinants of health (SDOH) are becoming increasingly recognised as mediators of human health. In the setting of metabolic dysfunction-associated steatotic liver disease (MASLD), most of the literature on SDOH relates to individual-level risk factors. However, there are very limited data on neighbourhood-level SDOH in MASLD.
aimTo assess whether SDOH impact fibrosis progression in patients who already have MASLD.
methodsThis was a retrospective cohort study of patients with MASLD seen at Michigan Medicine. The primary predictors were two neighbourhood-level SDOH, 'disadvantage' and 'affluence'. The primary outcomes were mortality, incident liver-related events (LREs) and incident cardiovascular disease (CVD). We modelled these outcomes using Kaplan-Meier statistics for mortality and competing risk analyses for LREs and CVD, using a 1-year landmark.
resultsWe included 15,904 patients with MASLD with median follow-up of 63 months. Higher affluence was associated with lower risk of overall mortality (hazard ratio 0.49 [0.37-0.66], p < 0.0001 for higher vs. lower quartile), LREs (subhazard ratio 0.60 [0.39-0.91], p = 0.02) and CVD (subhazard ratio 0.71 [0.57-0.88], p = 0.0018). Disadvantage was associated with higher mortality (hazard ratio 2.08 [95% confidence interval 1.54-2.81], p < 0.0001 for the highest vs. lowest quartile) and incident CVD (subhazard ratio 1.36 [95% confidence interval 1.10-1.68], p < 0.0001). These findings were robust across several sensitivity analyses. DISCUSSION: Neighbourhood-level SDOH are associated with mortality, incidence of LREs and incident CVD in patients with steatotic liver disease. Interventions aimed at disadvantaged neighbourhoods may improve clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.